Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + fulvestrant + pyrotinib for endocrine-resistant HR-positive/HER2-positive advanced breast cancer
ChiCTR2200055121Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib, fulvestrant and pyrotinib in breast cancer, sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
abemaciclibfulvestrantpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200055121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055121.